SCHEMBL3249142

SCHEMBL3249142

NC(=O)CN(c1ccc(Cl)cc1Cc1ccccc1Cl)S(=O)(=O)c1ccc2c(c1)OCCO2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 6/20 0.54
NFE2L2 Q16236 6/20 0.54
HSD11B1 P28845 1/20 0.43
ALDH1A1 P00352 7/20 0.43
GAA P10253 3/20 0.43
NPSR1 Q6W5P4 2/20 0.42
LMNA P02545 2/20 0.40
POLB P06746 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPT P10636 3/20 0.40
HTT P42858 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
USP2 O75604 1/20 0.40
TSHR P16473 1/20 0.39
HPGD P15428 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3253242 0.95 KEAP1 (0.55) KEAP1NFE2L2HSD11B1ALDH1A1GAA
SCHEMBL3253245 0.86 KEAP1 (0.51) KEAP1NFE2L2HPGD
SCHEMBL3255469 0.86 KEAP1 (0.43) KEAP1NFE2L2ALDH1A1GAALMNA
SCHEMBL3249159 0.84 KEAP1 (0.48) KEAP1NFE2L2ALDH1A1GAAPOLB
SCHEMBL4860804 0.83 KEAP1 (0.43) KEAP1NFE2L2ALDH1A1MAPTHPGD
SCHEMBL4872059 0.82 KEAP1 (0.52) KEAP1NFE2L2HSD11B1ALDH1A1GAA
SCHEMBL4867374 0.82 KEAP1 (0.43) KEAP1NFE2L2MAPTCYP3A4CYP2C19
SCHEMBL3247753 0.81 PKM (0.57) KEAP1NFE2L2POLBHPGD
SCHEMBL3247110 0.81 THRB (0.45) KEAP1NFE2L2MAPTHPGDMEN1
SCHEMBL3251187 0.81 THRB (0.44) KEAP1NFE2L2HSD11B1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 KEAP1 3317/4885NFE2L2 2700/4885HSD11B1 1060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.